

Table 2. Summary baseline characteristics of the eligible study population.

Baseline characteristics		Study population n = 678	
Sex: male n (%)		313 (46.2)	
Age: median (IQR)		46 (26, 60)	
BMI, median (IQR)		26.0 (22.9, 30.6)	
Rhinitis diagnosis or therapy, n(%)		305 (45.0)	
Smoking status, n(%)	Current Smoker	40 (5.9)	
	Ex-smoker	145 (21.4)	
	Non-smoker	477 (70.4)	
Exacerbations, n(%)	0	551 (81.3)	
	1	83 (12.2)	
	≥2	44 (6.5)	
SABA dose (mcg), n(%)	1-100	121 (17.8)	
	101-200	132 (19.5)	
	201-400	94 (13.9)	
	401+	47 (6.9)	
Average ICS Daily dose, (mcg) BDP- equivalent dose, n(%)	None	304 (44.8)	
	1-100	67 (9.9)	
	101-200	106 (15.6)	
	201-400	101 (14.9)	
	401+	100 (14.7)	
Asthma therapy, n(%)	None	197 (29.1)	
	SABA	120 (17.7)	
	±SABA ±SAMA	LTRA	8 (1.2%)
		ICS	163 (24.0)
		ICS+LABA	132 (19.5)
		ICS+LAMA	1 (0.1)
		ICS+LABA+LAMA	5 (0.7)
		ICS+LTRA	8 (1.2)
		ICS+LABA+LTRA	41 (6.0)
	ICS+LABA+LAMA+LTRA	1 (0.1)	
Other	2 (0.3)		